Please login to the form below
Kymriah
This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.
FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
and Legend Biotech’s Carvykti (ciltacabtagene autoleucel), Novartis’s Kymriah (tisagenlecleucel), and Gilead and Kite’s Yescarta’s Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
Latest news
-
Novartis announces promising five-year data for leukaemia treatment Kymriah
ALL, we have our strongest evidence yet that one-time treatment with Kymriah has curative potential,”. ... The data shows the potential of Kymriah as a cure, and as the only CAR T-cell therapy available for such patients who have previously had limited
-
Novartis’ Kymriah receives FDA approval to treat follicular lymphoma
The single-arm, open-label trial showed that 86% of patients administered Kymriah achieved a response, which included 68% who experienced a complete response. ... The European Commission approved Kymriah in the EU in early May 2022 to treat adult
-
EC approves Novartis’ Kymriah for advanced blood cancer
Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma. ... The approval of Kymriah in Europe brings patients closer to a potentially definitive therapy, providing us with hope for improved outcomes,” she added.
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
Novartis has also announced regulatory news for Kymriah (tisagenlecleucel), with the US Food and Drug Administration granting the cancer therapy priority review for patients with relapsed or refractory follicular lymphoma. ... The European Medicines
-
Roche bets on T-cell therapies with Adaptimmune deal
CAR-T therapies including Kymriah (tisagenlecleucel).
More from news
Approximately 17 fully matching, plus 67 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Collaborating with pharma companies, Oxford Biomedica uses its infrastructure to produce other companies’ licensed products, including Novartis’ Kymriah treatment (alongside other undisclosed CAR-T-related products).
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug,
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest from PMHub
-
Understanding the evolving CAR-T market
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... But, Novartis could not retain a monopoly in for long. After the approval of Kymriah, investors
-
Precision paediatrics: Treating patients with CAR-T
There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
